Thursday, July 02, 2015 4:31:11 PM
I’ve been honing my version of the Vascepa saga, and added remarks about death caused by the SPA rescission. I post it below, and welcome corrections and comments.
BTW, the Shawshank reference is very appropriate. I love that movie. Seemingly endless nightmares do end, and Amarin’s will.
My father suffered for years and eventually died from a series of strokes, and both my grandfathers died of CVD, so, as I wait my turn, I have strong feelings about CVD. (I already take Vascepa and B complex off-label based on advice from this board (thanks for that BTW), but my wife’s doctor won’t prescribe off-label.)
Life and Death Consequences of the Anchor SPA Recission
A crucial question I haven’t heard the FDA ask is how many lives are likely to be saved or lost by delaying access to Vascepa. We can make a quick but reasonable ballpark estimate.
Using round numbers, let’s assume a 5 year delay, ten million at-risk US patients after post-approval ramp-up (a small fraction of the Anchor population), modest 20% CVD risk reduction (less than JELIS attained with a lower dose), and a typical major cardiac event rate of 5% in 5 years (assuming 20% of events are fatal, which is low). As an exceptionally safe drug from a safe class of drugs, Vascepa has a negligible death rate.
With these assumptions, rescinding the SPA can be expected to cause in the ballpark of an additional 100,000 major strokes and heart attacks over a five year period, including 20,000 deaths [footnote: due to biological and marketing delays, each day of delay causes 10 expected deaths about 3 or 4 years later.]. Given the conservative assumptions, it could easily be several times that. With foreign markets often following US approvals, and the disincentive to future innovation, it’s not crazy to wonder if this one incident could cause a million deaths globally over the next 20 years, with millions more disabled.
But, it’s enough to consider the 20,000 preventable American deaths that seem quite certain within a few years (about three times more than the Iraqi and Afghan wars combined from 2001 to 2015). After REDUCE-IT, we’ll know better how many, but it will be too late to do much about it. It’s like a lifeguard forbidding good ropes to be thrown to drowning people until extra tests are completed, while the drowning people struggle with dangerous, useless, rotten ropes. Under our conservative assumptions, ten will slip beneath the waves daily for five years. As of mid-2015, over 6,000 have already been doomed since the delay began in December 2013.
Although we don’t know exactly who they are, these are thousands and thousands of real people with loved ones and hopes and dreams for a future they will never see because some people at the FDA have lost their way. We must help them get back on track. I believe they chose careers in medicine and public service to help people, not to cause death.
No one says not to test, but with so many lives at stake while we wait years for the results, doctors need access to the best available option based on current information, and they need unhindered access to that information.
Recent AMRN News
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM